Order byBest matchMost fresh
FDA to offer faster drug reviews to companies promoting ‘national priorities’
WASHINGTON (AP) — U.S. regulators will begin offering faster reviews to new medicines that administration officials deem as promoting “the health interests of Americans,” under a new initiative announced Tuesday.
FDA Announces New Vouchers to Cut Drug Reviews to Two Months
The US Food and Drug Administration announced a new national priority voucher plan that aims to cut drug review times to one to two months for companies it says are backing national interests.
STAT7h
FDA announces a new priority review program in bid to further administration goals
The FDA is launching a program to reward companies with accelerated drug review and speedy agency feedback, if their actions align with the FDA's national health priorities.
Stocktwits on MSN1h
Dyne Therapeutics Stock Drops After ‘Surprise’ Pivot In Primary Endpoint For Muscle Drug Trial
Shares of Dyne Therapeutics fell on Tuesday after the company revised the primary endpoint in the registrational expansion cohort of its Achieve trial for DYNE-101, a treatment for myotonic dystrophy type 1 (DM1).
MIT Technology Review4d
Here’s what food and drug regulation might look like under the Trump administration
Leaders of the FDA have published a list of new priorities for the agency. They want to deliver rapidly-approved cures and "unleash AI."
FDA announces sweeping changes to Drug Review process
The Food and Drug Administration has announced some major changes to the review process for drug developers in the United States.
US FDA to shorten review time for drug developers under new voucher program
The U.S. Food and Drug Administration said on Tuesday it is launching a program under which its commissioner can issue vouchers to companies to shorten their review time for
Feedback